Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation
Early detection of leukemia relapse after transplant—rather than mutation type—best predicts outcomes, guiding when closer monitoring matters most.
This multicenter study of 57 AML patients relapsing after transplant found that most exhibit genetic instability with new mutations, but relapse timing trumps evolutionary pattern in predicting survival. Early relapse (<6 months) conferred significantly higher mortality regardless of clonal evolution type.
What the study was
- Study design
- Retrospective multicenter cohort
- Population
- AML patients relapsing after allo-HCT
- Sample size
- 57
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Bone Marrow Transplantation
Why it surfaced
Clinically informative multicenter data on AML post-transplant relapse genetics from Freiburg/Dana-Farber. Highlights importance of early molecular monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.